The Prognostic Value of SOX2 Expression in Non-small Cell Lung Cancer: a Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 31

PMID 23990933

Citations 33

Authors

Yansu Chen

Yefei Huang

Yulin Huang

Junjie Chen

Shouyu Wang

Jianwei Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients.

Methods: Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters.

Results: A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08-25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47-0.89, P = 0.007, random-effect).

Conclusions: SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.

Citing Articles

Cell Therapy with Human Reprogrammed CD8 T-Cells Has Antimetastatic Effects on Lewis Lung Carcinoma in C57BL/6 Mice.

Skurikhin E, Pershina O, Ermakova N, Pakhomova A, Zhukova M, Pan E Int J Mol Sci. 2022; 23(24).

PMID: 36555420 PMC: 9779156. DOI: 10.3390/ijms232415780.

Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer.

Valerio-Fernandes A, Fonseca N, Goncalves N, Cruz A, Pereira M, Gregorio A Cancers (Basel). 2022; 14(9).

PMID: 35565346 PMC: 9101044. DOI: 10.3390/cancers14092217.

The Impact of Iron Chelators on the Biology of Cancer Stem Cells.

Szymonik J, Wala K, Gornicki T, Saczko J, Pencakowski B, Kulbacka J Int J Mol Sci. 2022; 23(1).

PMID: 35008527 PMC: 8745085. DOI: 10.3390/ijms23010089.

The role of autoantibody detection in the diagnosis and staging of lung cancer.

Wang Y, Jiao Y, Ding C, Sun W Ann Transl Med. 2022; 9(22):1673.

PMID: 34988182 PMC: 8667094. DOI: 10.21037/atm-21-5357.

SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression.

Hosseini-Khah Z, Babaei M, Tehrani M, Cucchiarini M, Madry H, Ajami A Curr Oncol. 2021; 28(4):3015-3029.

PMID: 34436030 PMC: 8395510. DOI: 10.3390/curroncol28040264.

References

Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y . Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 2012; 18(10):2987-96. DOI: 10.1158/1078-0432.CCR-11-2863. View

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y . Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009; 16(12):3488-98. DOI: 10.1245/s10434-009-0617-z. View

Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S . EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012; 11:73. PMC: 3497614. DOI: 10.1186/1476-4598-11-73. View

Cai Y, Zhang H, Zhang Z, Mu J, Li Z . Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma. Oncol Lett. 2012; 2(2):257-264. PMC: 3410566. DOI: 10.3892/ol.2010.229. View

Lu Y, Futtner C, Rock J, Xu X, Whitworth W, Hogan B . Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010; 5(6):e11022. PMC: 2883553. DOI: 10.1371/journal.pone.0011022. View

Coate L, John T, Tsao M, Shepherd F . Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009; 10(10):1001-10. DOI: 10.1016/S1470-2045(09)70155-X. View

Sasaki H, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y . Increased Sox2 copy number in lung squamous cell carcinomas. Exp Ther Med. 2012; 3(1):44-48. PMC: 3438854. DOI: 10.3892/etm.2011.374. View

Bass A, Watanabe H, Mermel C, Yu S, Perner S, Verhaak R . SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009; 41(11):1238-42. PMC: 2783775. DOI: 10.1038/ng.465. View

Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis L . Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010; 5(2):e9112. PMC: 2817751. DOI: 10.1371/journal.pone.0009112. View

10.

Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X . CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 2012; 62(4):496-508. DOI: 10.1136/gutjnl-2011-301522. View

11.

Alberg A, Ford J, Samet J . Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):29S-55S. DOI: 10.1378/chest.07-1347. View

12.

Cai Y, Zhang H, Qu Y, Mu J, Zhao D, Zhou L . Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep. 2011; 26(4):877-85. DOI: 10.3892/or.2011.1349. View

13.

Marques-Torrejon M, Porlan E, Banito A, Gomez-Ibarlucea E, Lopez-Contreras A, Fernandez-Capetillo O . Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. Cell Stem Cell. 2012; 12(1):88-100. PMC: 3714747. DOI: 10.1016/j.stem.2012.12.001. View

14.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H . Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2010; 73(1):110-5. DOI: 10.1016/j.lungcan.2010.11.004. View

15.

Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y . Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci. 2012; 13(6):7663-7675. PMC: 3397552. DOI: 10.3390/ijms13067663. View

16.

Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K . High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One. 2013; 8(4):e61427. PMC: 3631238. DOI: 10.1371/journal.pone.0061427. View

17.

Whitehead A, Whitehead J . A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991; 10(11):1665-77. DOI: 10.1002/sim.4780101105. View

18.

Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A . Lung Cancer: Are we up to the Challenge?. Curr Genomics. 2011; 11(7):513-8. PMC: 3048313. DOI: 10.2174/138920210793175903. View

19.

Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S . Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011; 6(11):1793-800. DOI: 10.1097/JTO.0b013e3182272273. View

20.

Wilbertz T, Wagner P, Petersen K, Stiedl A, Scheble V, Maier S . SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011; 24(7):944-53. DOI: 10.1038/modpathol.2011.49. View